» Articles » PMID: 31163981

Clinic-Based Strategies to Reach United States Million Hearts 2022 Blood Pressure Control Goals

Overview
Date 2019 Jun 6
PMID 31163981
Citations 32
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The Centers for Disease Control and Prevention's Million Hearts initiative includes an ambitious ≥80% blood pressure control goal in US adults with hypertension by 2022. We used the validated Blood Pressure Control Model to quantify changes in clinic-based hypertension management processes needed to attain ≥80% blood pressure control.

Methods And Results: The Blood Pressure Control Model simulates patient blood pressures weekly using 3 key modifiable hypertension management processes: office visit frequency, clinician treatment intensification given uncontrolled blood pressure, and continued antihypertensive medication use (medication adherence rate). We compared blood pressure control rates (using the Seventh Joint National Committee on hypertension targets) achieved over 4 years between usual care and the best-observed values for management processes identified from the literature (1-week return visit interval, 20%-44% intensification rate, and 76% adherence rate). We determined the management process values needed to achieve ≥80% blood pressure control in US adults. In adults with uncontrolled blood pressure, usual care achieved 45.6% control (95% uncertainty interval, 39.6%-52.5%) and literature-based best-observed values achieved 79.7% control (95% uncertainty interval, 79.3%-80.1%) over 4 years. Increasing treatment intensification rates to 62% of office visits with an uncontrolled blood pressure resulted in ≥80% blood pressure control, even when the return visit interval and adherence remained at usual care values. Improving to best-observed values for all 3 management processes would achieve 78.1% blood pressure control in the overall US population with hypertension, approaching the ≥80% Million Hearts 2022 goal.

Conclusions: Achieving the Million Hearts blood pressure control goal by 2022 will require simultaneously increasing visit frequency, overcoming therapeutic inertia, and improving patient medication adherence. As the relative importance of each of these 3 processes will depend on local characteristics, simulation models like the Blood Pressure Control Model can help local healthcare systems tailor strategies to reach local and national benchmarks.

Citing Articles

Cost-Effectiveness of a Polypill for Cardiovascular Disease Prevention in an Underserved Population.

Kohli-Lynch C, Moran A, Kazi D, Bibbins-Domingo K, Jordan N, French D JAMA Cardiol. 2025; 10(3):224-233.

PMID: 39775718 PMC: 11904704. DOI: 10.1001/jamacardio.2024.4812.


Trends in Blood Pressure Control among US Adults With Hypertension, 2013-2014 to 2021-2023.

Hardy S, Jaeger B, Foti K, Ghazi L, Wozniak G, Muntner P Am J Hypertens. 2024; 38(2):120-128.

PMID: 39504487 PMC: 11735471. DOI: 10.1093/ajh/hpae141.


Trends of Antihypertensive Prescription Among US Adults From 2010 to 2019 and Changes Following Treatment Guidelines: Analysis of Multicenter Electronic Health Records.

Lin P, Rifas-Shiman S, Merriman J, Petimar J, Yu H, Daley M J Am Heart Assoc. 2024; 13(9):e032197.

PMID: 38639340 PMC: 11179868. DOI: 10.1161/JAHA.123.032197.


Impact of a preventive cardiology clinic focusing on lifestyle and nutrition counseling: A pilot analysis.

Elzeneini M, George J, Ashraf H, Xu K, Petersen J, Anderson R Am Heart J Plus. 2024; 6:100032.

PMID: 38560555 PMC: 10976304. DOI: 10.1016/j.ahjo.2021.100032.


Association Between Self-Reported Medication Adherence and Therapeutic Inertia in Hypertension: A Secondary Analysis of SPRINT (Systolic Blood Pressure Intervention Trial).

Jacobs J, Derington C, Zheutlin A, King J, Cohen J, Bucheit J J Am Heart Assoc. 2024; 13(3):e031574.

PMID: 38240275 PMC: 11056166. DOI: 10.1161/JAHA.123.031574.


References
1.
Bild D, Bluemke D, Burke G, Detrano R, Diez Roux A, Folsom A . Multi-Ethnic Study of Atherosclerosis: objectives and design. Am J Epidemiol. 2002; 156(9):871-81. DOI: 10.1093/aje/kwf113. View

2.
. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002; 288(23):2981-97. DOI: 10.1001/jama.288.23.2981. View

3.
Law M, Wald N, Morris J, Jordan R . Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ. 2003; 326(7404):1427. PMC: 162261. DOI: 10.1136/bmj.326.7404.1427. View

4.
Wogen J, Kreilick C, Livornese R, Yokoyama K, Frech F . Patient adherence with amlodipine, lisinopril, or valsartan therapy in a usual-care setting. J Manag Care Pharm. 2003; 9(5):424-9. PMC: 10437241. DOI: 10.18553/jmcp.2003.9.5.424. View

5.
Chobanian A, Bakris G, Black H, Cushman W, Green L, Izzo Jr J . Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003; 42(6):1206-52. DOI: 10.1161/01.HYP.0000107251.49515.c2. View